| ￥990 在线订购包邮(港澳台除外) | |
| A02261-40 | |
|
|
|
|
|
|
|
|
|
| 咨询产品问题 | |
| Specificity | This product is specific for Zolbetuximab. |
| Host Species | Mouse |
| Immunogen | Zolbetuximab |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
|
|||||||||
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid repeated freezing and thawing cycles. |
| Purification | Protein A affinity column |
| Isotype | Mouse IgG1, κ |
| Clonality | Monoclonal |
| Clone ID | 9C9G2 |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
BLI (Biolayer interferometry) binding affinity measurements of Anti-Zolbetuximab Antibody (9C9), mAb, Mouse (GenScript, A02261) to Zolbetuximab.
Zolbetuximab captured on HFC (Anti-Human IgG Fc) Probes can bind Anti-Zolbetuximab Antibody (9C9), mAb, Mouse with a dissociation constant (KD) of less than 1 pM. »
Anti-Zolbetuximab Antibody (34E11) or (9C9) inhibits the binding of Zolbetuximab to Claudin18.2 (CLDN18.2).
Coating antigen: Zolbetuximab 1 µg/ml.
Claudin18.2 (GenScript, Z03504) final concentration: 1.2 µg/ml.
Anti-Zolbetuximab antibody dilutions start from 10 μg/ml.
Anti-Zolbetuximab Antibody (34E11), mAb, Mouse (GenScript, A02260) exhibited non-inhibitory properties, whereas Anti-Zolbetuximab Antibody (9C9), mAb, Mouse (GenScript, A02261) demonstrated significant inhibitory properties with an IC50 value of 0.44 µg/ml. »
Standard curve of Zolbetuximab sandwich ELISA by A02260 (34E11) and A02261 (9C9).
In this ELISA assay, Anti-Zolbetuximab Antibody (34E11), mAb, Mouse (GenScript, A02260) was coated at a concentration of 1 μg/ml, and Anti-Zolbetuximab Antibody (9C9), mAb, Mouse (GenScript, A02261) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/ml.
In this ELISA assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99984. The typicaldynamic range of the assay is 2-128 ng/mL and its sensitivity of detecting Zolbetuximab is up to 2 ng/ml. »
Specificity analysis of the detection of Zolbetuximab.
Zolbetuximab standard samples at 8 concentrations were spiked with 2 µg/mL of human IgG1. The test result demonstrated that the high concentration of human IgG1 did not interfere with the detection of Zolbetuximab.
In this ELISA assay, Anti-Zolbetuximab Antibody (34E11), mAb, Mouse (GenScript, A02260) was coated at a concentration of 1 μg/ml, and Anti-Zolbetuximab Antibody (9C9), mAb, Mouse (GenScript, A02261) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/ml. »
MRD analysis of the detection of Zolbetuximab in biological matrix.
The MRD is the minimum dilution necessary for the detection of Zolbetuximab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggestedthat MRD was as 1:20.
In this ELISA assay, Anti-Zolbetuximab Antibody (34E11), mAb, Mouse (GenScript, A02260) was coated at a concentration of 1 μg/ml, and Anti-Zolbetuximab Antibody (9C9), mAb, Mouse (GenScript, A02261) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/ml. »
| Target Background | Zolbetuximab, also known by its development code IMAB362, is a novel monoclonal antibody targeting Claudin-18 isoform 2 (Claudin-18.2). Currently, it is being studied for its potential in treating gastrointestinal adenocarcinomas and pancreatic tumors. |
| Synonyms | Zolbetuximab; claudiximab; GC-182; IMAB-362; IMAB362; Claudin-18.2 Inhibitor; anti-human Claudin-18.2; anti-Claudin18.2 antibody; anti-CLDN18 antibody, anti-SFTA5 antibody, anti-SFTPJ antibody |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
